Quantitative Investment Management LLC Sells 42,588 Shares of Becton, Dickinson and Company $BDX

Key Points

• Quantitative Investment Management cut its stake in Becton, Dickinson by 83.7%, selling 42,588 shares and leaving 8,273 shares worth about $1.55 million after the 3rd quarter.
• BDX beat quarterly estimates with EPS of $2.91 (vs. $2.81) and revenue of $5.25 billion (vs. $5.15B), and set FY2026 guidance of $12.350–$12.650 per share while analysts show an average "Hold" rating and $195.46 target.
• The company declared a $1.05 quarterly dividend (annualized $4.20, yield ~2.6%), authorized a $10 million buyback, and its shares traded near $159.37 (down ~2.3%), below the ~ $190 50‑ and 200‑day moving averages.

Quantitative Investment Management LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 83.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,273 shares of the medical instruments supplier's stock after selling 42,588 shares during the quarter. Quantitative Investment Management LLC's holdings in Becton, Dickinson and Company were worth $1,548,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BDX. Arrowstreet Capital Limited Partnership grew its holdings in shares of Becton, Dickinson and Company by 87.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 370,008 shares of the medical instruments supplier's stock worth $69,254,000 after purchasing an additional 172,663 shares during the last quarter. Keystone Financial Services increased its holdings in shares of Becton, Dickinson and Company by 18.4% in the third quarter. Keystone Financial Services now owns 4,176 shares of the medical instruments supplier's stock valued at $782,000 after purchasing an additional 648 shares in the last quarter. Sei Investments Co. raised its position in shares of Becton, Dickinson and Company by 14.7% during the third quarter. Sei Investments Co. now owns 188,224 shares of the medical instruments supplier's stock worth $35,227,000 after acquiring an additional 24,167 shares during the last quarter. Crux Wealth Advisors raised its holdings in Becton, Dickinson and Company by 23.1% during the 3rd quarter. Crux Wealth Advisors now owns 6,248 shares of the medical instruments supplier's stock worth $1,169,000 after purchasing an additional 1,173 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Becton, Dickinson and Company by 64.7% during the third quarter. UBS Group AG now owns 1,136,673 shares of the medical instruments supplier's stock worth $212,751,000 after buying an additional 446,676 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on BDX shares. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an "overweight" rating in a report on Tuesday, December 2nd. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, January 7th. Zacks Research downgraded Becton, Dickinson and Company from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 11th. Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an "overweight" rating and a $202.00 price target on the stock. Finally, Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating on the stock in a report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $195.46.

Becton, Dickinson and Company Stock Down 2.3%

Becton, Dickinson and Company stock opened at $159.37 on Friday. The company's 50-day moving average is $190.72 and its 200-day moving average is $190.28. The firm has a market capitalization of $45.38 billion, a PE ratio of 26.00, a P/E/G ratio of 11.83 and a beta of 0.24. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company's revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company's dividend payout ratio is 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock buyback program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares of the company's stock, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,610 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company's stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,416 shares of company stock valued at $674,693 over the last 90 days. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.